Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene Therapy That Overcomes Blood-Brain Barrier to Treat Central Nervous System Manifestations

12.10.2004


Mucopolysaccharidosis (MPS) type VII (also known as Sly syndrome) is a lysosomal storage disorder (LSD) characterized by a deficiency of the lysomal enzyme beta-glucuronidase. MPS VII leads to bone and joint abnormalities, enlargement of the visceral organs, cardiovascular disease and neurologic impairment. Using a MPS VII adult animal model, researchers in the Center for Gene Therapy at Columbus Children’s Research Institute (CCRI) on the campus of Columbus Children’s Hospital have demonstrated a gene therapy strategy whereby in vivo administration into the liver of a recombinant adeno-associated virus (rAAV) type 2 vector is capable of reversing the progression of storage in the liver, spleen, kidney, heart, lung and, importantly, the brain. This is the first time researchers have demonstrated that the peripheral in vivo administration of a therapeutic gene leads to improvement in the brain of an adult MPS VII animal model. The findings were published in the September issue of Molecular Therapy.



Previous work has shown that similar therapies are effective in treating the brain if administered soon after birth, but until now, it was believed that the blood-brain barrier would prevent this occurrence during adulthood.

“It’s not clearly understood why in newborns, the blood-brain barrier is ‘open,’ and as a person matures, very few substances can cross through this barrier,” said Thomas J. Sferra, M.D., gastroenterologist and associate professor at The Ohio State University College of Medicine and Public Health. “In our study, we were able to show an improvement in the manifestations of this disease within the brain. Now that we have proven that this type of therapy can overcome the blood-brain barrier, we can begin to study how this occurred. In the long-term, we have the potential to apply this type of therapy to a majority of the LSDs and even other disorders.”


Lysosomes are described as the cell’s “recycling center,” whereby enzymes continuously breakdown large molecules into smaller materials to be reused by the cell. LSDs are inherited disorders caused by a deficiency of one of the lysosomal enzymes. This deficiency interferes with the normal breakdown process causing an accumulation of abnormal molecules in the lysosomes. This accumulation prohibits normal function of the particular organ (such as the liver, spleen, bone, and brain) in which the storage occurs. There are more than 40 types of LSDs and the combined incidence of these diseases is one in every 8,000 live births.

For his research, Sferra conducted two studies in adult MPS VII animal models to test the effect of different amounts of the rAAV vector and to analyze the length of time for improvement of the disease to begin. To achieve the highest level of gene transfer upon administration, the vector was injected directly into the liver.

“After a single administration of the rAAV vector, we observed a reduction of lysosomal storage in every organ analyzed at two months post-injection. Importantly, this disease improvement was maintained for at least one year after vector administration,” said Sferra.

Currently, Sferra’s team is engaged in early studies using the rAAV vector as a transport mechanism to carry genes to treat other diseases.

Columbus Children’s ranks among the top 10 in National Institutes of Health research awards and grants to freestanding children’s hospitals in the country and houses the Department of Pediatrics of The Ohio State University College of Medicine and Public Health. With nearly 600,000 patient visits each year, Children’s Hospital is a 112-year-old pediatric healthcare network treating newborns through age 21. In 2003, the Columbus Children’s Research Institute conducted more than 300 research projects and is the home of Centers of Emphasis encompassing gene therapy; molecular and human genetics; vaccines and immunity; childhood cancer; cell and vascular biology; developmental pharmacology and toxicology; injury research and policy; biopathology; microbial pathogenesis; and biobehavioral health. Pediatric Clinical Trials International (PCTI), a site management organization affiliated with the hospital, also coordinated more than 50 clinical trials. In addition to having one of the largest ambulatory programs in the country, Children’s offers specialty programs and services. More than 75,000 consumers receive health and wellness education each year and affiliation agreements with nearly 100 institutions allow more than 1,700 students and 500 residents to receive training at Children’s annually. More information on Children’s Hospital of Columbus is available by calling (614) 722-KIDS (5437) or through the hospital’s Web site at http://www.columbuschildrens.com.

| newswise
Further information:
http://www.columbuschildrens.com

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>